Form 4: Beta Bionics CFO Sells Shares After Option Exercise

Beta Bionics CFO Stephen Feider exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged 10b5-1 plan.

Summary

• Stephen Feider, Chief Financial Officer of Beta Bionics, Inc. (BBNX), reported transactions on October 3, 2025.
• Feider exercised employee stock options to acquire 4,982 shares of common stock at an exercise price of $5.1 per share.
• Immediately following the option exercise, Feider sold a total of 4,982 shares of common stock.
• The sales were executed in two separate transactions under a Rule 10b5-1 trading plan adopted on May 15, 2025.
• 3,828 shares were sold at a weighted average price of $21.5172, with prices ranging from $21.04 to $22.0144.
• An additional 1,154 shares were sold at a weighted average price of $22.2778, with prices ranging from $22.0438 to $22.47.
• Following these transactions, Feider beneficially owns 44,041 shares of Beta Bionics common stock.
• Feider also holds employee stock options for 69,695 shares, which vest in 48 equal monthly installments from September 14, 2023.

Sentiment

Score: 5

Explanation: The transaction is neutral. It represents a planned insider sale following an option exercise, which is a common practice for executives to realize value from their compensation. The pre-arranged 10b5-1 plan mitigates concerns about opportunistic selling.

Positives

• The transactions were conducted under a pre-arranged Rule 10b5-1 plan, indicating a planned and systematic approach to managing equity holdings rather than a reaction to immediate market conditions.
• The exercise of options at $5.1 and subsequent sale at prices above $21 demonstrates a significant profit for the insider, reflecting potential value creation in the company's stock.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces the insider's direct equity stake in the company.

Risks

• Perception of reduced insider confidence due to the sale of shares, which could potentially influence investor sentiment.
• Potential for misinterpretation of the sales as a signal of future company performance, despite being pre-planned.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing reflects a routine insider transaction involving the exercise of stock options and subsequent sale of shares, a common practice for executives to manage their equity compensation and diversify personal holdings. It does not provide specific insights into broader industry trends or competitive positioning.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders may observe a slight reduction in direct insider ownership, though the pre-planned nature of the sale under a 10b5-1 plan typically lessens concerns about management's confidence in the company's future.

Next Steps

• The filing does not mention any specific future actions, events, or milestones for the company or the reporting person beyond the completion of these transactions.

Key Dates

Recommendation

The filing details a routine, pre-planned insider transaction (exercise of options and subsequent sale of shares) by the CFO. Such transactions, especially when executed under a Rule 10b5-1 plan, are generally not indicative of a change in the company's fundamental outlook or a lack of confidence from management. Therefore, based solely on this Form 4, there is no new information to warrant a change in investment thesis, suggesting a 'hold' recommendation.

Keywords

Beta Bionics, BBNX, Stephen Feider, CFO, Insider Trading, Form 4, Stock Option Exercise, Rule 10b5-1 Plan, Common Stock Sale, Beneficial Ownership